Testing the Effects of Low Dose Apalutamide on Prostate-Specific Antigen (PSA) Levels in Men Scheduled for Removal of the Prostate Gland
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04530552|
Recruitment Status : Recruiting
First Posted : August 28, 2020
Last Update Posted : March 8, 2023
- Study Details
- Tabular View
- No Results Posted
- How to Read a Study Record
|Condition or disease||Intervention/treatment||Phase|
|Localized Prostate Carcinoma Prostate Adenocarcinoma Stage I Prostate Cancer AJCC v8 Stage II Prostate Cancer AJCC v8 Stage IIIA Prostate Cancer AJCC v8 Stage IIIB Prostate Cancer AJCC v8||Drug: Apalutamide Procedure: Biospecimen Collection Other: Quality-of-Life Assessment||Phase 2|
I. To determine the effects of low dose apalutamide on circulating levels of prostate specific antigen (PSA).
I. To determine the effect of low dose apalutamide on:
Ia. Reversibility of testosterone levels 7-14 days post intervention; Ib. Post-intervention plasma trough apalutamide concentration; Ic. Health-related quality of life.
I. To determine the effects of apalutamide on intra-prostatic immune cell infiltration and Gleason score as exploratory endpoints.
Patients receive apalutamide orally (PO) on study. Patients also undergo collection of blood samples throughout the study.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||40 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Clinical Study of Bioactivity of Low Dose Apalutamide in Prostate Cancer Patients Scheduled for Prostatectomy|
|Actual Study Start Date :||June 1, 2021|
|Estimated Primary Completion Date :||August 31, 2024|
|Estimated Study Completion Date :||August 31, 2024|
Experimental: Treatment (apalutamide)
Patients receive apalutamide PO on study. Patients also undergo collection of blood samples throughout the study.
Procedure: Biospecimen Collection
Undergo collection of blood samples
Other: Quality-of-Life Assessment
Other Name: Quality of Life Assessment
- Change in prostate specific antigen (PSA) levels [ Time Frame: Baseline up to end of treatment ]The proportion of participants with >= 25% decline in PSA levels (from baseline to end-of-intervention) will be reported along with the 97.5% credible interval for the response rate based on the posterior distribution of the response rate derived from a non-informative prior for the response rate, which is consistent with the Bayesian approach.
- Reversibility of testosterone levels [ Time Frame: Baseline, and at 7-14 days post-intervention (post-operative) ]The post-operative testosterone levels will be compared with the levels at baseline and end-of-intervention within each dose cohort. Paired t test will be performed on the changes in testosterone to evaluate the effects of low dose apalutamide for each dose group. A 95% CI will be reported for each of the two dose groups.
- Post-intervention plasma trough apalutamide concentrations [ Time Frame: Up to 7-14 days after prostate surgery ]Post-intervention plasma trough apalutamide concentrations will be quantified by a sensitive and specific liquid chromatography mass spectrometry assay. The correlation between plasma trough apalutamide and the change of PSA levels will be assessed. Pearson correlation coefficient will be derived to evaluate the correlation between the plasma trough apalutamide levels and the change of PSA levels. A 95% CI will be reported for each of the two dose groups.
- Health-related quality of life (HRQOL) [ Time Frame: Baseline, until end of intervention ]HRQOL will be assessed by a validated questionnaire (Expanded Prostate Cancer Index Composite for Clinical Practice [EPIC-CP]) to allow for efficient and accurate measurement of urinary incontinence, urinary irritation, bowel, sexual, and hormonal HRQOL in prostate cancer patients. Changes (from baseline to end-of-intervention) in the overall score and subscore for each measure will be assessed for each dose group. Changes in EPIC-CP (from baseline to end-of-intervention) in the overall score and sub-score for each measure will be derived and paired t test will be performed to evaluate the change for each dose group. A 95% CI will be reported for each of the two dose groups.
- Gleason score of pre- and post-intervention tumor(s) with matched location [ Time Frame: Up to 7-14 days after prostate surgery ]Changes (from most recent biopsy to prostatectomy) in the Gleason score of pre- and post-intervention tumor(s) with matched location will be assessed for each dose group. Linear mixed effects model with a random intercept accounting within-subject dependence will be performed to compare the change in Gleason score of pre- and post-intervention tumor(s) with matched location since a participant can have more than one tumor. A 95% CI will be reported for each of the two dose groups.
- Intra-prostatic immune cell infiltration [ Time Frame: Up to 7-14 days after prostate surgery ]CD8+, CD4+, and CD56+ positive cells in the prostate tissues will be assessed by immunohistochemistry. Changes (from most recent biopsy to prostatectomy) in these immune cells will be assessed for each dose group. Changes in immune cell infiltration will also be assessed in a subgroup of participants where materials are available from pre- and post-intervention tumor(s) with matched location. Changes (from most recent biopsy to prostatectomy) in these immune cells will be assessed for each dose group by paired t test. A 95% CI will be reported for each of the two dose groups.
- Effects of tobacco/alcohol use [ Time Frame: Baseline, every 7-10 during study, within 3 days prior to surgery, and 7-14 days after surgery ]Will be assessed by examining the associations between tobacco and alcohol consumption and the effects of apalutamide on the study endpoints.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||18 Years and older (Adult, Older Adult)|
|Sexes Eligible for Study:||Male|
|Accepts Healthy Volunteers:||No|
- Histologically confirmed organ-confined adenocarcinoma of the prostate (PCa) suitable for prostatectomy
- Gleason score =< (4+4), however no Gleason pattern 5
- Current serum PSA =< 20 ng/ml
- Age > 18 years
- Karnofsky >= 70%
- Leukocytes >= 3,000/uL
- Absolute neutrophil count >= 1,500/uL
- Platelets >= 100,000/uL
- Total bilirubin =< 1.5 x institutional upper limit of normal (ULN) (note: in subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =< 1.5 x ULN, subject may be eligible)
- Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamic pyruvic transaminase [SGPT]) < 2.5 x institutional ULN
- Creatinine < 2 x institutional ULN
- Thyroid stimulating hormone (TSH) within the institutional normal range
- Willing to use adequate contraception (barrier method; abstinence; subject has had a vasectomy; or partner is using effective birth control or is postmenopausal) for the duration of study participation
- Ability to understand and the willingness to sign a written informed consent document
- Prior or ongoing hormonal treatment for prostate cancer including, but not limited to orchiectomy, antiandrogens, abiraterone, ketoconazole, or estrogens, or luteinizing hormone-releasing hormone (LHRH) agonists/antagonists. Men on stable doses of 5-alpha reductase inhibitors (e.g., finasteride, dutasteride) are eligible as long as there is no planned dose change while on study
- Patients who have prostate cancer with distant metastases
- Presence of neuroendocrine differentiation in the prostate biopsies
- Serum testosterone (blood collected between 7-10 AM for men < 45 years of age and prior to 2 PM for men >= 45 years of age) < 200 ng/dL
- Have a history of prior malignancies other than prostate cancer within the past 2 years, excluding non-melanoma skin cancer
- Severe or unstable angina, myocardial infarction, symptomatic congestive heart failure, arterial or venous thromboembolic events (e.g., pulmonary embolism, cerebrovascular accident including transient ischemic attacks), or clinically significant ventricular arrhythmias within 6 months prior to registration
- History of seizure or known condition that may pre-dispose to seizure (including but not limited to prior stroke, transient ischemic attack, loss of consciousness within 1 year prior to registration, brain arteriovenous malformation; or intracranial masses such as schwannomas and meningiomas that are causing edema or mass effect)
- Use of drugs known to lower the seizure threshold, including: atypical antipsychotics (e.g. clozapine, olanzapine, risperidone, ziprasidone), bupropion, lithium, meperidine, pethidine, phenothiazine antipsychotics (e.g. chlorpromazine, mesoridazine, thioridazine), and tricyclic antidepressants (e.g. amitriptyline, desipramine, doxepin, imipramine, maprotiline, mirtazapine)
- Concurrent use of drugs in category X drug interactions with apalutamide
- Participants may not be receiving any other investigational agents
- History of allergic reactions attributed to compounds of similar chemical composition of apalutamide
- Uncontrolled intermittent illnesses or medical conditions which, in the opinion of the treating physician, would make this protocol unreasonably hazardous for the patient. Such illnesses/conditions may include, but are not limited to, hypertension, ongoing or active infection, or psychiatric illness/social situations
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04530552
|United States, Arizona|
|University of Arizona Cancer Center - Prevention Research Clinic||Recruiting|
|Tucson, Arizona, United States, 85719|
|Contact: Hsiao-Hui (Sherry) Chow 520-626-3358 firstname.lastname@example.org|
|Principal Investigator: Hsiao-Hui (Sherry) Chow|
|United States, California|
|USC / Norris Comprehensive Cancer Center||Recruiting|
|Los Angeles, California, United States, 90033|
|Contact: Mike M. Nguyen 323-865-3041 Mike.Nguyen@med.usc.edu|
|Principal Investigator: Mike M. Nguyen|
|UC San Diego Medical Center - Hillcrest||Not yet recruiting|
|San Diego, California, United States, 92103|
|Contact: John K. Parsons 858-822-7874 K0parsons@mail.ucsd.edu|
|Principal Investigator: John K. Parsons|
|United States, District of Columbia|
|George Washington University Medical Center||Not yet recruiting|
|Washington, District of Columbia, United States, 20037|
|Contact: Michael J. Whalen 202-741-3121 email@example.com|
|Principal Investigator: Michael J. Whalen|
|United States, Maryland|
|Johns Hopkins University/Sidney Kimmel Cancer Center||Recruiting|
|Baltimore, Maryland, United States, 21287|
|Contact: Christian P. Pavlovich 410-550-3338 firstname.lastname@example.org|
|Principal Investigator: Christian P. Pavlovich|
|NCI - Center for Cancer Research||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Contact: Peter A. Pinto 301-496-6353 email@example.com|
|Principal Investigator: Peter A. Pinto|
|Principal Investigator:||Juan Chipollini||University of Arizona Cancer Center - Prevention Research Clinic|
|Responsible Party:||National Cancer Institute (NCI)|
|Other Study ID Numbers:||
NCI-2020-06322 ( Registry Identifier: CTRP (Clinical Trial Reporting Program) )
2102475889 ( Other Identifier: University of Arizona Cancer Center - Prevention Research Clinic )
UAZ20-01-01 ( Other Identifier: DCP )
P30CA023074 ( U.S. NIH Grant/Contract )
UG1CA242596 ( U.S. NIH Grant/Contract )
|First Posted:||August 28, 2020 Key Record Dates|
|Last Update Posted:||March 8, 2023|
|Last Verified:||November 2022|
|Individual Participant Data (IPD) Sharing Statement:|
|Plan to Share IPD:||Yes|
|Plan Description:||NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.|
|Studies a U.S. FDA-regulated Drug Product:||Yes|
|Studies a U.S. FDA-regulated Device Product:||No|
Genital Neoplasms, Male
Neoplasms by Site